文献
J-GLOBAL ID:202202276904052768
整理番号:22A1026556
KEYNOTE-181研究に基づく進行食道癌患者におけるペブロリズマブの費用効果分析【JST・京大機械翻訳】
Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
著者 (6件):
Zhan Mei
(Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China)
,
Zhan Mei
(West China School of Pharmacy, Sichuan University, Chengdu, China)
,
Xu Ting
(Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China)
,
Zheng Hanrui
(Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China)
,
Zheng Hanrui
(West China School of Pharmacy, Sichuan University, Chengdu, China)
,
He Zhiyao
(Department of Pharmacy, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China)
資料名:
Frontiers in Public Health (Web)
(Frontiers in Public Health (Web))
巻:
10
ページ:
790225
発行年:
2022年
JST資料番号:
U7097A
ISSN:
2296-2565
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
スイス (CHE)
言語:
英語 (EN)